CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy
Science Immunology · 2024
DOI: 10.1126/sciimmunol.adp6529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Steven P Wolf und 11 weiteren Autor:innen. Beteiligte Einrichtung: David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Cancers eventually kill hosts even when infiltrated by cancer-specific T cells. We examined whether cancer-specific T cell receptors of CD4 + T cells (CD4TCRs) from tumor-bearing hosts can be exploited for adoptive TCR therapy. We focused on CD4TCRs targeting an autochthonous mutant neoantigen that is only presented by stroma surrounding the MHC class II–negative cancer cells. The 11 most common tetramer-sorted CD4TCRs were tested using TCR-engineered CD4 + T cells. Three TCRs were characterized by convergent recombination for which multiple T cell clonotypes differed in their nucleotide sequences but encoded identical TCR α and β chains. These preferentially selected TCRs destroyed tumors equally well and halted progression through reprogramming of the tumor stroma. TCRs represented by single T cell clonotypes were similarly effective only if they shared CDR elements with preferentially selected TCRs in both α and β chains. Selecting candidate TCRs on the basis of these characteristics can help identify TCRs that are potentially therapeutically effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA.
- Department of Pathology, University of Chicago, Chicago, IL, USA.
- Institute of Immunology, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, Berlin, Germany.
- German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-shi, Osaka, Japan.
ORCID-Profile: Steven P Wolf, Matthias Leisegang, Madeline Steiner, Veronika Wallace, Kazuma Kiyotani, Yifei Hu, Jun Huang, Karin Schreiber, Yusuke Nakamura, Andrea Schietinger, Hans Schreiber
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- ORFDO NIH HHS
- NIDA NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Wolf, S. P., Leisegang, M., Steiner, M., Wallace, V., Kiyotani, K., Hu, Y., Rosenberger, L., Huang, J., Schreiber, K., Nakamura, Y., Schietinger, A., & Schreiber, H. (2024). CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Science Immunology. https://doi.org/10.1126/sciimmunol.adp6529
Vancouver
Wolf SP, Leisegang M, Steiner M, Wallace V, Kiyotani K, Hu Y, et al. CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy. Science Immunology. 2024. doi:10.1126/sciimmunol.adp6529
BibTeX
@article{Wolf2024,
author = {Wolf, Steven P and Leisegang, Matthias and Steiner, Madeline and Wallace, Veronika and Kiyotani, Kazuma and Hu, Yifei and Rosenberger, Leonie and Huang, Jun and Schreiber, Karin and Nakamura, Yusuke and Schietinger, Andrea and Schreiber, Hans},
title = {CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy},
journal = {Science Immunology},
year = {2024},
doi = {10.1126/sciimmunol.adp6529}
}
EUVIMED